The proposed adjustment to the classification of cannabis by the Trump administration aims to position the substance on the same regulatory level as over-the-counter medications such as Tylenol with codeine. This change would represent a fundamental shift, as it could facilitate increased access and ease the regulatory burdens associated with cannabis. Such a move signifies the most substantial alteration in U.S. drug policy since the Controlled Substances Act was enacted in 1971, potentially impacting legal, medical, and commercial landscapes across the country. The proposal is part of ongoing discussions regarding federal perspectives on cannabis, which historically have ranged from strict prohibition to more permissive approaches. This adjustment could lead to changes in research permissions, medical use regulations, and market access, aligning federal policy closer with certain state-level regulations that have varied significantly over recent years.